We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
SBWIC
626
Schaper Benz & Wise Investment Counsel
Wisconsin
$6.76M -$147K -5,039 -2%
SCM
627
Salem Capital Management
Massachusetts
$6.71M +$29.9K +1,028 +0.4%
GCP
628
GSA Capital Partners
United Kingdom
$6.69M +$6.7M +230,320 New
Capital Fund Management (CFM)
629
Capital Fund Management (CFM)
France
$6.66M +$6.67M +229,214 New
ECM
630
Evergreen Capital Management
Washington
$6.65M -$1.64M -56,212 -20%
GT
631
Glenview Trust
Kentucky
$6.64M +$6.65M +228,594 New
AAP
632
Ardsley Advisory Partners
Connecticut
$6.58M -$920K -31,620 -12%
SLF
633
Sun Life Financial
Ontario, Canada
$6.58M -$2.02M -69,568 -23%
WJA
634
Williams Jones & Associates
New York
$6.58M -$58.8K -2,020 -0.9%
BOTW
635
Bank of the West
California
$6.57M +$373K +12,832 +6%
AIP
636
Ameritas Investment Partners
Nebraska
$6.55M +$160K +5,507 +3%
CVM
637
Cheviot Value Management
California
$6.48M -$135K -4,627 -2%
FMLI
638
Fukoku Mutual Life Insurance
Japan
$6.44M -$230K -7,905 -3%
DY
639
Dowling & Yahnke
California
$6.42M +$610K +20,943 +10%
GIM
640
Grassi Investment Management
California
$6.4M +$90.1K +3,095 +1%
VC
641
V2 Capital
Illinois
$6.31M +$6.32M +217,166 New
CA
642
Continental Advisors
Utah
$6.3M -$460K -15,810 -7%
FAAS
643
First Allied Advisory Services
California
$6.28M -$3.35M -115,173 -35%
Northwestern Mutual Wealth Management
644
Northwestern Mutual Wealth Management
Wisconsin
$6.28M +$564K +19,365 +10%
TCM
645
Tran Capital Management
California
$6.27M -$309K -10,619 -5%
SC
646
Saiers Capital
New York
$6.21M -$10.6M -363,946 -63%
BAC
647
Boys Arnold & Co
North Carolina
$6.19M +$70K +2,405 +1%
BCM
648
Birmingham Capital Management
Alabama
$6.15M -$302K -10,367 -5%
CA
649
Callahan Advisors
Texas
$6.14M -$21.1K -725 -0.3%
FAAM
650
First Allied Asset Management
California
$6.14M +$247K +8,470 +4%

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.